Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Quadion is a broad-spectrum topical antifungal medication developed and marketed by the Argentine pharmaceutical company Fortbenton Co. S.A. It is formulated as a shampoo containing 2% ketoconazole, a synthetic imidazole-derivative antifungal agent. Quadion is specifically indicated for the treatment and prophylaxis of scalp conditions associated with the yeast *Pityrosporum ovale* (also known as *Malassezia*), including dandruff and seborrheic dermatitis. The mechanism of action involves the inhibition of the fungal enzyme cytochrome P450-dependent 14α-demethylase, which is essential for converting lanosterol to ergosterol. The resulting deficiency in ergosterol disrupts the integrity and fluidity of the fungal cell membrane, leading to inhibited growth and cell death. The product is typically applied to the affected areas of the scalp, left for five minutes, and then rinsed, with a standard treatment frequency of twice weekly.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Quadion.